SIETES :: 92717 citas

Resultados de la búsqueda por ANSIEDAD REFINAR BÚSQUEDA

1.

Josephson CB, Engbers JDT, Jette N, Patten SB, Sinqh S, Sajobi TT, Marshall D, Agha-Khani Y, Federico P, Mackie A, Macrodimitris S, McLane B, Pillay N, Sharma R, Wiebe S. Prediction tools for psychiatric adverse effects after levetiracetam prescription. JAMA Neurology 2019:enero. [Ref.ID 103020]

2.

Ortiz de Landaluce L, Carbonell P, Asensio C, Escoda N, López P, Laporte JR. Gabapentin and pregabalin and risk of atrial fibrillation in the elderly: a population-based cohort study in an electronic prescription database. Drug Saf 2018;41:diciembre. [Ref.ID 102913]

3.

Watson S, Härmark L. Desogestrel and panic attacks – a new suspected adverse drug reaction reported by patients and health care professionals on spontaneous reports. Br J Clin Pharmacol 2018;84:agosto. [Ref.ID 102860]

4.

Begley S. ‘Microdosing’ is touted by ’shroomers and Reddit users. Science is starting to test their claims — and finding some truth. STAT 2018:23 de agosto. [Ref.ID 102810]

5.

Cohen LS, Góez-Mogollón L, Sosinsky AZ, Savella GM, Viguera AC, Chitayat D, Hernández-Díaz S, Freeman MP. Risk of major malformations in infants following first-trimester exposure to quetiapine. Am J Psychiatry 2018:16 de agosto. [Ref.ID 102798]

6.

Batelaan NM, Bosman RC, Muntingh A, Scholten WD, Huijbregts KM, van Balkom AJLM. Risk of relapse after antidepressant discontinuation in anxiety disorders, obsessive-compulsive disorder, and post-traumatic stress disorder: systematic review and meta-analysis of relapse prevention trials. BMJ 2017;358:j3927. [Ref.ID 102068]

7.

Ford BM, Tai S, Fantegrossi WE, Prather PL. Synthetic pot: not your grandfathers marijuana. Trends Pharmacol Sci 2017;38:257-76. [Ref.ID 101989]

8.

Anónimo. Psilocybin may reduce depression and anxiety in some cancer patients, studies suggest. DIA Daily 2016:1. [Ref.ID 100992]

9.

Anónimo. Pfizer loses UK appeal over pregabalin patent dispute. DIA Daily 2016:1. [Ref.ID 100808]

10.

Rubin R. Senators urge expedited evaluation of medical use of cannabidiol. JAMA 2016;316:13 de julio. [Ref.ID 100491]

11.

Bradford AC, Bradford D. Medical marijuana laws reduce prescription medication use In Medicare Part D. Health Affairs 2016;37:julio. [Ref.ID 100483]

12.

Lazarus B, Chen Y, Wilson FP, Sang Y, Chang AR, Coresh J, Grams ME. Proton pump inhibitor use and the risk of chronic kidney disease. JAMA Intern Med 2016;176:238246. [Ref.ID 100117]

13.

Ee C, Xue C, Chondros P, Myers SP, French SD, Teede H, Pirotta M. Acupuncture for menopausal hot flashes: a randomized trial. Ann Intern Med 2016;164:146-54. [Ref.ID 100116]

14.

Aldea Perona A, García-Sáiz M, Sanz Álvarez E. Psychiatric disorders and montelukast in children: a disproportionality analysis of the VigiBase. Drug Saf 2016;39:69-78. [Ref.ID 100084]

15.

Dubicka B, Cole-King A, Reynolds S, Ramchandani P. Paper on suicidality and aggression during antidepressant treatment was flawed and the press release was misleading. BMJ 2016;352:i911. [Ref.ID 100053]

16.

Sharma T, Guski LS, Freund N, Gotzsche PC. Suicidality and aggression during antidepressant treatment: systematic review and meta-analyses based on clinical study reports. BMJ 2016;352:i65. [Ref.ID 100036]

17.

Moncrieff J. Misrepresenting harms in antidepressant trials. BMJ 2016;352:i217. [Ref.ID 100033]

18.

Hill KP. Medical marijuana for treatment of chronic pain and other medical and psychiatric problems: a clinical review. JAMA 2015;313:2474-83. [Ref.ID 99309]

19.

Whiting PF, Wolff RF, Deshpande S, Di Nisio M, Duffy S, Hernandez AV, Keurentjes JC, Lang S, Misso K, Ryder S D, Schmidikofer S, Westwood M, Kleijnen J. Cannabinoids for medical use: a systematic review and meta-analysis. JAMA 2015;313:2456-73. [Ref.ID 99308]

20.

Young K. FDA advisers back approval of first drug for female sexual dysfunction. Journal Watch 2015:1. [Ref.ID 99241]